SHAREHOLDER ALERT: Investigation on Behalf of AcelRx Pharmaceuticals, Inc. Investors Announced by Law Offices of Howard G. Sm...
September 29 2014 - 2:45PM
Business Wire
Law Offices of Howard G. Smith announces that it is
investigating potential claims on behalf of purchasers of the
securities of AcelRx Pharmaceuticals, Inc. (“AcelRx” or the
“Company”) (NASDAQ:ACRX) concerning possible violations of federal
securities laws. The investigation is focused on certain statements
issued by AcelRx concerning the Company’s operations and financial
prospects. AcelRx is a development-stage specialty pharmaceutical
company, focused on therapies for the treatment of acute and
breakthrough pain.
The investigation is related to AcelRx’s announcement that the
Company’s New Drug Application (NDA) for Zalviso™ (sufentanil
sublingual tablet system) will qualify as a Class 2 resubmission
with a review period of six months. According to a press release
issued by AcelRx on September 26, 2014, the Company is targeting
resubmission of the NDA for first quarter 2015 or later, subject to
feedback from the FDA. Following this announcement, AcelRx shares
dropped nearly 20%, or $1.31 per share, on extremely heavy
volume.
The Company previously announced in a July 28, 2014, regulatory
filing that it anticipated resubmitting the NDA by the end of 2014,
after receiving a Complete Response Letter from the FDA requesting
additional information on the Zalviso System concerning proper use
of the device, optical system errors, changes to the instructions
for use of the device, and submission of additional data to support
the shelf life of the product.
If you purchased AcelRx securities between December 2, 2013 and
September 26, 2014, if you have information or would like to learn
more about these claims, or if you have any questions concerning
this announcement or your rights or interests with respect to these
matters, please contact Howard G. Smith, Esquire, of Law Offices of
Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem,
Pennsylvania 19020 by telephone at (215) 638-4847, Toll Free at
(888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or
visit our website at www.howardsmithlaw.com.
Law Offices of Howard G. SmithHoward G. Smith, Esquire(215)
638-4847(888)
638-4847howardsmith@howardsmithlaw.comwww.howardsmithlaw.com
AcelRX Pharmaceuticals (NASDAQ:ACRX)
Historical Stock Chart
From Aug 2024 to Sep 2024
AcelRX Pharmaceuticals (NASDAQ:ACRX)
Historical Stock Chart
From Sep 2023 to Sep 2024